The Chinese government has been encouraging overseas pharmaceutical companies to outsource R&D to Chinese firms—part of an effort to move into more high-value work. The draw: a growing, cost-effective bioscience talent pool made up of both local graduates and “sea turtles” who went to U.S. universities and returned, according to Morrison & Foerster partner Gordon… Continue Reading